GB201621398D0 - Treatment of emt-associated disease - Google Patents
Treatment of emt-associated diseaseInfo
- Publication number
- GB201621398D0 GB201621398D0 GBGB1621398.5A GB201621398A GB201621398D0 GB 201621398 D0 GB201621398 D0 GB 201621398D0 GB 201621398 A GB201621398 A GB 201621398A GB 201621398 D0 GB201621398 D0 GB 201621398D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- emt
- treatment
- associated disease
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/52—Isomerases (5)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y502/00—Cis-trans-isomerases (5.2)
- C12Y502/01—Cis-trans-Isomerases (5.2.1)
- C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1621398.5A GB201621398D0 (en) | 2016-12-15 | 2016-12-15 | Treatment of emt-associated disease |
PCT/GB2017/053763 WO2018109491A1 (en) | 2016-12-15 | 2017-12-15 | Treatment of emt-associated disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1621398.5A GB201621398D0 (en) | 2016-12-15 | 2016-12-15 | Treatment of emt-associated disease |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201621398D0 true GB201621398D0 (en) | 2017-02-01 |
Family
ID=58284347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1621398.5A Ceased GB201621398D0 (en) | 2016-12-15 | 2016-12-15 | Treatment of emt-associated disease |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201621398D0 (en) |
WO (1) | WO2018109491A1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190127805A1 (en) * | 2016-03-15 | 2019-05-02 | Almac Diagnostics Limited | Gene signatures for cancer detection and treatment |
-
2016
- 2016-12-15 GB GBGB1621398.5A patent/GB201621398D0/en not_active Ceased
-
2017
- 2017-12-15 WO PCT/GB2017/053763 patent/WO2018109491A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2018109491A1 (en) | 2018-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1251257A1 (en) | Use of exosomes for the treatment of disease | |
ZA202006746B (en) | Methods of treatment | |
IL253945B (en) | Kdm1a inhibitors for the treatment of disease | |
PT3212233T (en) | Combination therapy for treatment of disease | |
HK1258994A1 (en) | Methods for treatment of diseases | |
HK1249865B (en) | Treatment of pain | |
GB201618424D0 (en) | Treatment of antibody mediated disease | |
GB201412578D0 (en) | Treatment of neurological diseases | |
PL3484475T3 (en) | 1-methylnicotinamide for the treatment of cardiovascular disease | |
GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
GB201515244D0 (en) | Treatment of inflammatory disease or condition | |
SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
HK1243937A1 (en) | Methods of treating diseases | |
GB201410407D0 (en) | Treatment of chagas disease | |
SI3302499T1 (en) | Treatment of mitochondrial diseases | |
GB201412010D0 (en) | Treatment of hypertransaminasemia | |
GB201622116D0 (en) | Treatment of liver disease | |
GB201604359D0 (en) | Treatment of tissue disorders | |
GB201512139D0 (en) | Methods of treatment | |
GB201621398D0 (en) | Treatment of emt-associated disease | |
IL263837A (en) | Treatment of ocular disease | |
IL272422A (en) | Methods for the treatment of leptomeningeal disease | |
GB201504413D0 (en) | Treatment of disease | |
GB201610938D0 (en) | Treatment of ocular disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
COOA | Change in applicant's name or ownership of the application |
Owner name: ALMAC DISCOVERY LIMITED Free format text: FORMER OWNER: ALMAC DIAGNOSTICS LIMITED |
|
AT | Applications terminated before publication under section 16(1) |